Navigation Links
Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
Date:10/29/2008

rk in the biotechnology industry will be a great resource in our oncology drug development efforts."

Dr. Waksal is the author of 50 published scientific papers, many in the area of oncology. He currently serves on a number of non-corporate boards, including the American Committee for the Weizmann Institute of Science in New York, NY, Oberlin College in Oberlin, OH and the Montclair Art Museum in Montclair, NJ. Dr. Waksal also serves on the Technology Advisory Board for the New Jersey Edison Innovation Fund.

He earned his B.A. in biology from Oberlin College in 1975, and received his M.D. from Tufts University School of Medicine, Boston, MA.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
2. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
3. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
4. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
5. Senesco Technologies to Present at BIO 2008 Business Forum
6. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
7. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
8. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
9. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
10. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
11. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Research and Markets  has announced the ... Strategic Business Report" report to their offering. ... Supplies in US$ Thousands by the following Product Segments: Media, Sera, ... the US, Canada , Japan ... and Latin America . Annual estimates and forecasts ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
(Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
(Date:8/18/2014)... , Aug. 18, 2014 BioElectronics ... advanced consumer medical devices said that its ... interviewed by CEOLIVE.TV as part of its ... interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... explains to investors the unique advantages of ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... Calif., May 6 Nektar Therapeutics (Nasdaq: NKTR ... ended March 31, 2009. Net loss for the quarter ended ... compared to net loss of $40.7 million or $0.44 per ... made improvements to its operating efficiencies as compared to a ...
... Bill Clinton will,participate as one of the main speakers at ... 3 in Sao Paulo, Brazil. The event is organized by ... most,important gatherings focused on biofuels in the world. , ... awarded a second term,in six decades. After leaving the White ...
... ChanTest, the leading expert in ion channels and GPCRs ... and safety -- is one of eight organizations slated ... Commercialization Program. Governor Ted Strickland and Interim Director of ... Ohio Third Frontier Commission, Mark Barbash, announced the competitive ...
Cached Biology Technology:Nektar Therapeutics Reports First Quarter 2009 Financial Results 2Nektar Therapeutics Reports First Quarter 2009 Financial Results 3Nektar Therapeutics Reports First Quarter 2009 Financial Results 4Nektar Therapeutics Reports First Quarter 2009 Financial Results 5Nektar Therapeutics Reports First Quarter 2009 Financial Results 6Nektar Therapeutics Reports First Quarter 2009 Financial Results 7Nektar Therapeutics Reports First Quarter 2009 Financial Results 8Nektar Therapeutics Reports First Quarter 2009 Financial Results 9President Bill Clinton to Speak at the Ethanol Summit in Brazil 2ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 2ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 3
(Date:8/19/2014)... A new study of 9- and 10-year-olds finds ... fibrous and compact white-matter tracts in the brain than ... the bundles of axons that carry nerve signals from ... is associated with faster and more efficient nerve activity. ... open-access journal Frontiers in Human Neuroscience. , "Previous ...
(Date:8/18/2014)... in a person,s gut may protect against or increase ... of human bacterial intestinal inflammation, according research published this ... of the American Society for Microbiology. The study also ... changes to one,s gut bacteria composition. , "It has ... or microorganisms in the gut, can protect a person ...
(Date:8/18/2014)... the Earth,s land mass is made up of rangelands, ... transformed at an alarming rate. Woody plants, such as ... leading to a loss of critical habitat and causing ... produce food specifically meat. , Researchers with ... investigation that quantified this loss in both the United ...
Breaking Biology News(10 mins):Physically fit kids have beefier brain white matter than their less-fit peers 2Physically fit kids have beefier brain white matter than their less-fit peers 3What's in your gut? Certain bacteria may influence susceptibility to infection 2Trees and shrubs invading critical grasslands, diminish cattle production 2Trees and shrubs invading critical grasslands, diminish cattle production 3
... A new study suggests that jewel scarab beetles find ... that creates the 3D effects for the blockbuster movie ... Texas, the jewel scarab species Chrysina gloriosa ... ability could provide the beetles with a tremendous advantage, ...
... Lovn Centre for Marine Sciences at the University of Gothenburg ... in the Gullmarsfjord north of Gothenburg. The bacterium has been ... marine research center. Researcher Matthias Obst from the ... at the Sven Lovn Centre for Marine Sciences, a new ...
... Boston, MA A tobacco company,s new, dissolvable ... but which in some cases resembles popular candies--could lead ... new study from the Harvard School of Public Health ... for Disease Control and Prevention (CDC) and the Food ...
Cached Biology News:Beetles stand out using 'Avatar' tech 2Tobacco company's new, dissolvable nicotine products could lead to accidental poisoning 2
... SeeDNA co-precipitant, 250 ul ... color ensures easy pellet ... acid recovery.Chemically inert, compatible ... applications.Simple 5-minute protocol. Category: ...
EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Recombinant Mouse sTNF RII/TNFRSF1B...
Mouse Wnt-11 Affinity Purified Polyclonal Ab...
Biology Products: